Faculty, Staff and Student Publications

Publication Date

2-1-2025

Journal

American Journal of Hematology

Abstract

Patients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND-AML patients treated with Ven-HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery. Multivariable analysis-derived hazard ratios (HR), including 1.8 for European LeukemiaNet (ELN) adverse karyotype, 4.7 for KMT2Ar, 1.7 for TP53

Keywords

Humans, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Middle Aged, Sulfonamides, Female, Aged, Male, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Young Adult, DNA Methylation, karyotype, mutations, remission, survival, venetoclax

DOI

10.1002/ajh.27564

PMID

39671248

PMCID

PMC11705209

PubMedCentral® Posted Date

12-13-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.